Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 16/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | OXTR | P30559 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095191 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR2KCNH2OXTR | |
| Hydrochloric Acid SCHEMBL5102018 | 0.99 | AVPR1A (0.98) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5098355 | 0.93 | AVPR1A (0.86) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5094840 | 0.93 | AVPR1A (0.86) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5108491 | 0.89 | AVPR1A (0.81) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5107939 | 0.89 | AVPR1A (0.81) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL5101519 | 0.89 | AVPR1A (0.80) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL20727308 | 0.89 | AVPR1A (0.80) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL8325451 | 0.89 | AVPR1A (0.79) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5098204 | 0.88 | AVPR1A (1.00) | AVPR1AAVPR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247037-B2 | 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders | Neumora Therapeutics, Inc. (US) | 2025-03-11 | — | — | US | disclosed |
| US-12152038-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| CN-118108723-A | Triazolobenzodiazepine compound and preparation method and application thereof | 暨南大学附属第一医院（广州华侨医院） | 2024-05-31 | — | — | CN | disclosed |
| EP-3894414-B1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | NEUMORA THERAPEUTICS INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3679043-B9 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | NEUMORA THERAPEUTICS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3679043-B1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | NEUMORA THERAPEUTICS INC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230093235-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2023-03-23 | — | — | US | disclosed |
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| US-20230084719-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| CN-111212842-B | Vasopressin receptor antagonists and products and methods related thereto | 布莱克索恩治疗公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152038-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885AVPR2 2/4885KCNH2 482/4885 |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | AVPR1A 2/4885AVPR2 3/4885KCNH2 413/4885 |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | AVPR1A 2/4885AVPR2 3/4885KCNH2 635/4885 |
| US-12247037-B2 | 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders | AVPR1B, AVPR1A, AVPR2 | AVPR1A 2/4885AVPR2 3/4885KCNH2 968/4885 |
| US-20230093235-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1B, AVPR1A, AVPR2 | AVPR1A 2/4885AVPR2 3/4885KCNH2 635/4885 |
| US-20230084719-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | AVPR1B, AVPR1A, AVPR2 | AVPR1A 2/4885AVPR2 3/4885KCNH2 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.